LIVIVO - Search results -

Search results

Result 1 - 10 of total 44

Search options

Article ; Online: SIT1 transporter as a potential novel target in treatment of COVID-19.

Semiz, Sabina

2021 Volume 12, Issue 1, Page(s) 156–163

Abstract: Studies published earlier this year demonstrated the association of the solute ... ...

Abstract	Studies published earlier this year demonstrated the association of the solute carrier
MeSH term(s)	COVID-19/genetics ; COVID-19/therapy ; Diabetes Mellitus, Type 2/genetics ; Diabetes Mellitus, Type 2/therapy ; Glycine/blood ; Humans ; Membrane Transport Proteins/genetics
Chemical Substances	Membrane Transport Proteins ; SLC6A20 protein, human ; Glycine (TE7660XO1C)
Language	English
Publishing date	2021-12-30
Publishing country	Germany
Document type	Journal Article
ZDB-ID	2557908-3
ISSN	1868-503X ; 1868-5021
ISSN (online)	1868-503X
ISSN	1868-5021
DOI	10.1515/bmc-2021-0017
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 7056: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Vanadium as potential therapeutic agent for COVID-19: A focus on its antiviral, antiinflamatory, and antihyperglycemic effects.

Semiz, Sabina

Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS)

2021 Volume 69, Page(s) 126887

Abstract: An increasing evidence suggests that vanadium compounds are novel potential drugs in the treatment of diabetes, atherosclerosis, and cancer. Vanadium has also demonstrated activities against RNA viruses and is a promising candidate for treating acute ... ...

Abstract	An increasing evidence suggests that vanadium compounds are novel potential drugs in the treatment of diabetes, atherosclerosis, and cancer. Vanadium has also demonstrated activities against RNA viruses and is a promising candidate for treating acute respiratory diseases. The antidiabetic, antihypertensive, lipid-lowering, cardioprotective, antineoplastic, antiviral, and other potential effects of vanadium are summarized here. Given the beneficial antihyperglycemic and antiinflammatory effects as well as the potential mechanistic link between the COVID-19 and diabetes, vanadium compounds could be considered as a complement to the prescribed treatment of COVID-19. Thus, further clinical trials are warranted to confirm these favorable effects of vanadium treatment in COVID-19 patients, which appear not to be studied yet.
MeSH term(s)	Anti-Inflammatory Agents/pharmacology ; Antiviral Agents/pharmacology ; COVID-19/drug therapy ; Diabetes Mellitus/drug therapy ; Humans ; Hypoglycemic Agents/pharmacology ; SARS-CoV-2 ; Vanadium/pharmacology ; Vanadium Compounds/pharmacology
Chemical Substances	Anti-Inflammatory Agents ; Antiviral Agents ; Hypoglycemic Agents ; Vanadium Compounds ; Vanadium (00J9J9XKDE)
Language	English
Publishing date	2021-10-29
Publishing country	Germany
Document type	Journal Article ; Review
ZDB-ID	1236267-0
ISSN	1878-3252 ; 1611-602X ; 0946-672X
ISSN (online)	1878-3252 ; 1611-602X
ISSN	0946-672X
DOI	10.1016/j.jtemb.2021.126887
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2279: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: SIT1 transporter as a potential novel target in treatment of COVID-19

Semiz Sabina

Biomolecular Concepts, Vol 12, Iss 1, Pp 156-

2021 Volume 163

Abstract: Studies published earlier this year demonstrated the association of the solute carrier SLC6A20 gene with the risk and severity of COVID-19. The SLC6A20 protein product (Sodium-dependent Imino Transporter 1 (SIT1)) is involved in the transport of amino ... ...

Abstract	Studies published earlier this year demonstrated the association of the solute carrier SLC6A20 gene with the risk and severity of COVID-19. The SLC6A20 protein product (Sodium-dependent Imino Transporter 1 (SIT1)) is involved in the transport of amino acids, including glycine. Here we summarized the results of recent studies demonstrating the interaction of SIT1 with the ACE2 receptor for SARS-CoV-2 as well as an observed association of SLC6A20 with the risk and traits of Type 2 diabetes (T2D). Recently, it was also proposed that SLC6A20 represents the novel regulator of glycine levels and that glycine has beneficial effects against the proinflammatory cytokine secretion induced by SARS-CoV-2 infection. Ivermectin, as a partial agonist of glycine-gated chloride channels, was also recently suggested to interfere with the COVID-19 cytokine storm by inducing the activation of glycine receptors. Furthermore, plasma glycine levels are found to be decreased in diabetic patients. Thus, further clinical trials are warranted to confirm the potential favorable effects of targeting the SIT1 transporter and glycine levels in the treatment of COVID-19, particularly for the severe case of disease associated with hyperglycemia, inflammation, and T2D. These findings suggest that SIT1 may potentially represent one of the missing pieces in the complex puzzle observed between these two pandemic diseases and the potential novel target for their efficient treatment.
Keywords	slc6a20 ; sars-cov-2 ; diabetes ; glycine ; ivermectin ; Biology (General) ; QH301-705.5
Subject code	500
Language	English
Publishing date	2021-12-01T00:00:00Z
Publisher	De Gruyter
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: Prevention and Management of Type 2 Diabetes and Metabolic Syndrome in the Time of COVID-19: Should We Add a Cup of Coffee?

Semiz, Sabina / Serdarevic, Fadila

Frontiers in nutrition

2020 Volume 7, Page(s) 581680

Abstract: Recent evidence shows that COVID-19 patients with existing metabolic disorders, such as diabetes and metabolic syndrome, are exposed to a high risk of morbidity and mortality. At the same time, in order to manage the pandemic, the health authorities ... ...

Abstract	Recent evidence shows that COVID-19 patients with existing metabolic disorders, such as diabetes and metabolic syndrome, are exposed to a high risk of morbidity and mortality. At the same time, in order to manage the pandemic, the health authorities around the world are advising people to stay at home. This results in decreased physical activity and an increased consumption of an unhealthy diet, which often leads to an increase in body weight, risk for diabetes, insulin resistance, and metabolic syndrome, and thus, paradoxically, to a high risk of morbidity and mortality due to COVID-19 complications. Here we summarize the evidence demonstrating that the promotion of a healthy life style, including physical activity and a dietary intake of natural polyphenols present in coffee and tea, has the potential to improve the prevention and management of insulin resistance and diabetes in the time of COVID-19 pandemic. Particularly, it would be pertinent to evaluate further the potential positive effects of coffee beverages, rich in natural polyphenols, as an adjuvant therapy for COVID-19, which appear not to be studied sufficiently.
Keywords	covid19
Language	English
Publishing date	2020-10-06
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2776676-7
ISSN	2296-861X
ISSN	2296-861X
DOI	10.3389/fnut.2020.581680
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Prevention and Management of Type 2 Diabetes and Metabolic Syndrome in the Time of COVID-19

Sabina Semiz / Fadila Serdarevic

Frontiers in Nutrition, Vol

Should We Add a Cup of Coffee?

2020 Volume 7

Abstract	Recent evidence shows that COVID-19 patients with existing metabolic disorders, such as diabetes and metabolic syndrome, are exposed to a high risk of morbidity and mortality. At the same time, in order to manage the pandemic, the health authorities around the world are advising people to stay at home. This results in decreased physical activity and an increased consumption of an unhealthy diet, which often leads to an increase in body weight, risk for diabetes, insulin resistance, and metabolic syndrome, and thus, paradoxically, to a high risk of morbidity and mortality due to COVID-19 complications. Here we summarize the evidence demonstrating that the promotion of a healthy life style, including physical activity and a dietary intake of natural polyphenols present in coffee and tea, has the potential to improve the prevention and management of insulin resistance and diabetes in the time of COVID-19 pandemic. Particularly, it would be pertinent to evaluate further the potential positive effects of coffee beverages, rich in natural polyphenols, as an adjuvant therapy for COVID-19, which appear not to be studied sufficiently.
Keywords	polyphenols ; coffee ; COVID-19 ; ACE2 ; type 2 diabetes ; obesity ; Nutrition. Foods and food supply ; TX341-641 ; covid19
Subject code	910
Language	English
Publishing date	2020-10-01T00:00:00Z
Publisher	Frontiers Media S.A.
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Prevention and Management of Type 2 Diabetes and Metabolic Syndrome in the Time of COVID-19

Semiz, Sabina / Serdarevic, Fadila

Frontiers in Nutrition

Should We Add a Cup of Coffee?

2020 Volume 7

Keywords	covid19
Publisher	Frontiers Media SA
Publishing country	ch
Document type	Article ; Online
ZDB-ID	2776676-7
ISSN	2296-861X
ISSN	2296-861X
DOI	10.3389/fnut.2020.581680
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Order via subito

Details ▾
- Full text online
- Order with fees

Article ; Online: Precision medicine in the era of CRISPR-Cas9

Sabina Semiz / Philip C. Aka

Palgrave Communications, Vol 5, Iss 1, Pp 1-

evidence from Bosnia and Herzegovina

2019 Volume 8

Abstract: Abstract This article explores the possibilities and challenges of genetic testing, genetic counseling, and genome editing (collectively referred to in this piece as precision medicine) in Bosnia and Herzegovina, in the era of CRISP-Cas9. It is informed ... ...

Abstract	Abstract This article explores the possibilities and challenges of genetic testing, genetic counseling, and genome editing (collectively referred to in this piece as precision medicine) in Bosnia and Herzegovina, in the era of CRISP-Cas9. It is informed by recent developments in the field which reached new heights in the radar of global awareness in the wake of the research scandal from China in November of 2018. The scandal generated intense debates, some of it still ongoing, regarding the appropriate boundaries for scientific research on human DNA. Bearing on independent developments within this country, complemented with global events, the article covers several grounds related to the topic, including: the nature and limits of emerging legislation; measures of genetic testing and genetic counseling; public engagement meant to increase awareness among stakeholders, beginning with the public, regarding these novel technologies; and corresponding bioethical and social implications. BH decision makers must work to ensure that socioeconomic factors do not pose obstacles to healthcare access, including matters bordering on precision medicine, and they must strive to realize standards for citizens, whether in healthcare delivery, research, or general educational services, that do not lag behind the rest of Europe. The route to reaching these governance goals will be through well-timed legislation, level-headed implementation, and diligent legislative oversight of the work of administrative agencies.
Keywords	Social Sciences ; H
Subject code	360
Language	English
Publishing date	2019-10-01T00:00:00Z
Publisher	Palgrave Macmillan
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Effects of combined treatment of probiotics and metformin in management of type 2 diabetes: A systematic review and meta-analysis.

Memon, Hamda / Abdulla, Fatima / Reljic, Tea / Alnuaimi, Saif / Serdarevic, Fadila / Asimi, Zelija Velija / Kumar, Ambuj / Semiz, Sabina

Diabetes research and clinical practice

2023 Volume 202, Page(s) 110806

Abstract: Background: Lifestyle changes and dietary intervention, including the use of probiotics, can modulate dysbiosis of gut microbiome and contribute to the management of type 2 diabetes mellitus (T2DM). This systematic review and meta-analysis aim to assess ...

Abstract	Background: Lifestyle changes and dietary intervention, including the use of probiotics, can modulate dysbiosis of gut microbiome and contribute to the management of type 2 diabetes mellitus (T2DM). This systematic review and meta-analysis aim to assess the efficacy of metformin plus probiotics versus metformin alone on outcomes in patients with T2DM. Methods: We searched MEDLINE and EMBASE from inception to February 2023 to identify all randomized controlled trials (RCTs), which compared the use of metformin plus probiotics versus metformin alone in adult patients with T2DM. Data were summarized as mean differences (MD) with 95 % confidence interval (CI) and pooled under the random effects model. Findings: Fourteen RCTs (17 comparisons, 1009 patients) were included in this systematic review. Pooled results show a significant decrease in fasting glucose (FG) (MD = -0.64, 95 % CI = -1.06, -0.22) and HbA1c (MD = -0.29, 95 % CI = -0.47, -0.10) levels in patients with T2DM treated with metformin plus probiotics versus metformin alone. The addition of probiotics to metformin resulted in lower odds of gastrointestinal adverse events (Odds ratio = 0.18, 95 % CI = 0.09, 0.3.8; I Conclusions: The addition of probiotics to metformin therapy is associated with improvement in T2DM outcomes. However, high-quality and adequately reported RCTs are needed in the future to confirm our findings.
MeSH term(s)	Adult ; Humans ; Metformin/therapeutic use ; Hypoglycemic Agents/therapeutic use ; Diabetes Mellitus, Type 2/drug therapy ; Diabetes Mellitus, Type 2/chemically induced ; Probiotics/therapeutic use ; Fasting
Chemical Substances	Metformin (9100L32L2N) ; Hypoglycemic Agents
Language	English
Publishing date	2023-06-25
Publishing country	Ireland
Document type	Meta-Analysis ; Systematic Review ; Journal Article ; Review
ZDB-ID	632523-3
ISSN	1872-8227 ; 0168-8227
ISSN (online)	1872-8227
ISSN	0168-8227
DOI	10.1016/j.diabres.2023.110806
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2047: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: PPAR agonists as add-on treatment with metformin in management of type 2 diabetes: a systematic review and meta-analysis.

Alnuaimi, Saif / Reljic, Tea / Abdulla, Fatima S / Memon, Hamda / Al-Ali, Sarah / Smith, Teagen / Serdarevic, Fadila / Velija Asimi, Zelija / Kumar, Ambuj / Semiz, Sabina

Scientific reports

2024 Volume 14, Issue 1, Page(s) 8809

Abstract: The combination of metformin and the peroxisome proliferator-activated receptors (PPAR) agonists offers a promising avenue for managing type 2 diabetes (T2D) through their potential complementary mechanisms of action. The results from randomized ... ...

Abstract	The combination of metformin and the peroxisome proliferator-activated receptors (PPAR) agonists offers a promising avenue for managing type 2 diabetes (T2D) through their potential complementary mechanisms of action. The results from randomized controlled trials (RCT) assessing the efficacy of PPAR agonists plus metformin versus metformin alone in T2D are inconsistent, which prompted the conduct of the systematic review and meta-analysis. We searched MEDLINE and EMBASE from inception (1966) to March 2023 to identify all RCTs comparing any PPAR agonists plus metformin versus metformin alone in T2D. Categorical variables were summarized as relative risk along with 95% confidence interval (CI). Twenty RCTs enrolling a total of 6058 patients met the inclusion criteria. The certainty of evidence ranged from moderate to very low. Pooled results show that using PPAR agonist plus metformin, as compared to metformin alone, results in lower concentrations of fasting glucose [MD = - 22.07 mg/dl (95% CI - 27.17, - 16.97), HbA1c [MD = - 0.53% (95% CI - 0.67, - 0.38)], HOMA-IR [MD = - 1.26 (95% CI - 2.16, - 0.37)], and fasting insulin [MD = - 19.83 pmol/L (95% CI - 29.54, - 10.13)] without significant increase in any adverse events. Thus, synthesized evidence from RCTs demonstrates the beneficial effects of PPAR agonist add-on treatment versus metformin alone in T2D patients. In particular, novel dual PPARα/γ agonist (tesaglitazar) demonstrate efficacy in improving glycaemic and lipid concentrations, so further RCTs should be performed to elucidate the long-term outcomes and safety profile of these novel combined and personalized therapeutic strategies in the management of T2D.PROSPERO registration no. CRD42023412603.
MeSH term(s)	Humans ; Metformin/therapeutic use ; Peroxisome Proliferator-Activated Receptors ; Hypoglycemic Agents/therapeutic use ; Diabetes Mellitus, Type 2/drug therapy ; Diabetes Mellitus, Type 2/chemically induced ; Drug Therapy, Combination
Chemical Substances	Metformin (9100L32L2N) ; Peroxisome Proliferator-Activated Receptors ; Hypoglycemic Agents
Language	English
Publishing date	2024-04-16
Publishing country	England
Document type	Meta-Analysis ; Systematic Review ; Journal Article
ZDB-ID	2615211-3
ISSN	2045-2322 ; 2045-2322
ISSN (online)	2045-2322
ISSN	2045-2322
DOI	10.1038/s41598-024-59390-z
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Drug interactions with statins.

Causevic-Ramosevac, Anida / Semiz, Sabina

Acta pharmaceutica (Zagreb, Croatia)

2013 Volume 63, Issue 3, Page(s) 277–293

Abstract: The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) are generally well tolerated as monotherapy. Statins are associated with two important adverse effects, asymptomatic elevation in liver enzymes and myopathy. Myopathy is ... ...

Abstract	The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) are generally well tolerated as monotherapy. Statins are associated with two important adverse effects, asymptomatic elevation in liver enzymes and myopathy. Myopathy is most likely to occur when statins are administered with other drugs. Statins are substrates of multiple drug transporters (including OAT- -P1B1, BCRP and MDR1) and several cytochrome P450 (CYP) enzymes (including CYP3A4, CYP2C8, CYP2C19, and CYP2C9). Possible adverse effects of statins can occur due to interactions in concomitant use of drugs that substantially inhibit or induce their methabolic pathway. This review summarizes the most important interactions of statins.
MeSH term(s)	Animals ; Anti-Arrhythmia Agents/metabolism ; Anti-Arrhythmia Agents/therapeutic use ; Anti-Bacterial Agents/metabolism ; Anti-Bacterial Agents/therapeutic use ; Cytochrome P-450 Enzyme System/metabolism ; Drug Interactions/physiology ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/metabolism ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use ; Hypercholesterolemia/drug therapy ; Hypercholesterolemia/metabolism ; Protease Inhibitors/metabolism ; Protease Inhibitors/therapeutic use ; Substrate Specificity/drug effects
Chemical Substances	Anti-Arrhythmia Agents ; Anti-Bacterial Agents ; Hydroxymethylglutaryl-CoA Reductase Inhibitors ; Protease Inhibitors ; cytochrome P-450 CYP2C subfamily ; Cytochrome P-450 Enzyme System (9035-51-2)
Language	English
Publishing date	2013-09
Publishing country	Croatia
Document type	Journal Article ; Review
ZDB-ID	1111806-4
ISSN	1846-9558 ; 1330-0075
ISSN (online)	1846-9558
ISSN	1330-0075
DOI	10.2478/acph-2013-0022
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 1904: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito